Literature DB >> 9778047

Overexpression of AML1 renders a T hybridoma resistant to T cell receptor-mediated apoptosis.

M Fujii1, K Hayashi, M Niki, N Chiba, K Meguro, K Endo, J Kameoka, S Ito, K Abe, T Watanabe, M Satake.   

Abstract

The AML1 gene, which encodes the DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF, is involved in several types of chromosomal translocations associated with human acute myeloid leukemia, and has been shown by gene targeting to be essential for the development of definitive hematopoiesis in the murine fetal liver. In addition, the gene is expressed abundantly in T lymphocytes and has been implicated in T cell specific gene expression. In the present study we examined the function of AML1 in T cell receptor (TCR)-mediated, Fas/Fas-ligand dependent apoptosis of a T hybridoma line, DO11.10. Several independent cell clones overexpressing the AML1 protein were isolated by transfecting AML1 cDNA into these cells. These clones possessed an increased level of PEBP2/CBF DNA binding activity and were found to be resistant to apoptosis induced by anti-CD3 antibody treatment. Northern blot analysis revealed that induction of the Fas-ligand transcript was markedly suppressed in the anti-CD3 treated clones. Instead, expression of IL-2 receptor alpha subunit (IL-2R alpha), which is a manifestation of proliferative TCR signaling, was induced. This was in contrast to the parental, anti-CD3 treated DO11.10 cells where induction of Fas-ligand but not of IL-2R alpha was observed. Resistance of the AML1 overexpressing cell clones to TCR-mediated apoptosis is most likely attributable to the lack of Fas-ligand induction, since simultaneous treatment with anti-CD3 and anti-Fas antibodies caused apoptosis of the clones. The overall results suggest that the AML1 protein may play a pivotal role in switching TCR signaling between apoptosis and cell proliferation in T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778047     DOI: 10.1038/sj.onc.1202087

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Interplay of transcription factors in T-cell differentiation and function: the role of Runx.

Authors:  Won Fen Wong; Kazuyoshi Kohu; Tomoki Chiba; Takehito Sato; Masanobu Satake
Journal:  Immunology       Date:  2010-11-23       Impact factor: 7.397

2.  Runx regulation of sphingolipid metabolism and survival signaling.

Authors:  Anna Kilbey; Anne Terry; Alma Jenkins; Gillian Borland; Qifeng Zhang; Michael J O Wakelam; Ewan R Cameron; James C Neil
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

3.  AML1/Runx1 is important for the development of hindbrain cholinergic branchiovisceral motor neurons and selected cranial sensory neurons.

Authors:  Francesca M Theriault; Priscillia Roy; Stefano Stifani
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

4.  Roles of AML1/RUNX1 in T-cell malignancy induced by loss of p53.

Authors:  Kimiko Shimizu; Kazutsune Yamagata; Mineo Kurokawa; Shuki Mizutani; Yukiko Tsunematsu; Issay Kitabayashi
Journal:  Cancer Sci       Date:  2013-06-20       Impact factor: 6.716

5.  Mutations in lozenge and D-Pax2 invoke ectopic patterned cell death in the developing Drosophila eye using distinct mechanisms.

Authors:  Nicole A Siddall; Kristina Jackson Behan; Jennifer R Crew; Tara L Cheung; Jason A Fair; Philip Batterham; John Archie Pollock
Journal:  Dev Genes Evol       Date:  2003-02-22       Impact factor: 0.900

6.  Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage.

Authors:  Kerri E Rieger; Wan-Jen Hong; Virginia Goss Tusher; Jean Tang; Robert Tibshirani; Gilbert Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-19       Impact factor: 11.205

7.  Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor.

Authors:  Deli Hong; Andrew J Fritz; Kristiaan H Finstad; Mark P Fitzgerald; Adam Weinheimer; Adam L Viens; Jon Ramsey; Janet L Stein; Jane B Lian; Gary S Stein
Journal:  Mol Cancer Res       Date:  2018-08-06       Impact factor: 5.852

8.  Collaboration of MYC and RUNX2 in lymphoma simulates T-cell receptor signaling and attenuates p53 pathway activity.

Authors:  Jodie Hay; Kathryn Gilroy; Camille Huser; Anna Kilbey; Alma Mcdonald; Amanda MacCallum; Ailsa Holroyd; Ewan Cameron; James C Neil
Journal:  J Cell Biochem       Date:  2019-06-30       Impact factor: 4.429

9.  The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression.

Authors:  Okiru Komine; Keitaro Hayashi; Waka Natsume; Toshio Watanabe; Youichi Seki; Noriyasu Seki; Ryoji Yagi; Wataru Sukzuki; Hidekazu Tamauchi; Katsuto Hozumi; Sonoko Habu; Masato Kubo; Masanobu Satake
Journal:  J Exp Med       Date:  2003-06-30       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.